The pathogenesis and molecular biology of Down's syndrome are under intense study and advances have been made in the care of patients with Down's syndrome. Patients with Down's syndrome may exhibit cognitive impairment and developmental cognitive disorder; post-mortem brain tissue from patients who were older than 40 years may show senile plaques and neurofibrillary tangles as found in Alzheimer's disease. Skeletal and soft tissue abnormalities appear as well. Particular patients may have only mild cognitive disability; however, some patients may exhibit psychiatric disorders including autism and major depression. Most often, Down's syndrome is a noninherited chromosome disorder caused during meiosis by chromosome 21 nondisjunction. This leads to chromosome 21 trisomy. However, there is also an inherited form of Down's syndrome that is due to translocation of a fragment of chromosome 21 onto chromosome 14. The chromosome 21 fragment is from the 21q22 band-region and causes a triplication of that 1,000 bp portion of chromosome 21. However, there are indications that the two types of Down's syndrome are clinically indistinguishable [1, 2] MicroRNAs(miRNAs) are noncoding RNAs that are involved in gene expression regulation. They have been identified in several cell processes including DNA damage, synapse formation, neurotransmission, neural network plasticity, and CNS (central nervous system) development. MiRNA levels change during neurodegeneration. In greater detail, the genes that are perturbed by changes in the expression of the above five miRNAs in Down's syndrome include the following proteins: methyl CpG binding protein 2 (MeCP2), complement factor H (CFH), sirtuin 1 (SIRT1) ,phosphatidylinositol-binding clathrin assembly protein (PICALM), cyclin-dependent kinase inhibitor 2A (CDKN2A), glutamate receptor, ionotropic, N-methyl d-aspartate subunit 2A, (NR2A), Ephrin type A receptor 4 (EPHA4), Nestin (NES), transforming growth factor-β (TGF-β), toll-like receptor 7 (TLR7), cortactin-binding protein 2 (CTTNBP2), ankyrin 2 (ANK2), sodium-calcium exchanger 1 (Ncx1), tyrosine-(Y)-phosphorylation regulated kinase 1A gene (Dyrk1a), and nuclear factor of activated T-cells (NFAT).
Is it possible to correct or reverse the pathogenesis of Down's syndrome? We conclude this brief report with a few remarkable findings related to chromosome inactivation that indicate it may be just a matter of time prior to being able to cure this complex disease/syndrome.
Human females, diploid in the X chromosome, utilize the Xist gene (X-chromosome inactivation specific transcript (nonprotein coding) for expression suppression (inactivation, transcription silencing) of one of the X chromosomes. The X chromosome location of the Xist gene is at cytogenetic band Xq13.2 [6]. In addition, it should be noted, remarkably, that the RNA gene product of this gene is non-coding. The X chromosome silencing is effected by Xist non-coding RNA and is associated with chromatin modification. This serves as the canonical mechanism of chromosome inactivation [7] . Recent work has remarkably applied this model of transcriptional silencing to the problem of supernumerary gene expression in Down's syndrome. Pluripotent stem cells from Downs's syndrome patients were used as follows. Via editing zinc finger nucleases on chromosome 21 in these cell cultures, a Xist non-coding transgene was inserted into the DYRK1A (dualspecificity tyrosine-(Y)-phosphorylation regulated kinase 1A) locus. This step itself is notable as it amounts to the genetic reengineering of a specific chromosome. The chromosome 21 location of DYRK1A is at cytogenetic band 21q22. Figure 1C indicates the input interactions among Xist and two proteins with which it interacts. The two protein are NXF1 (nuclear RNA export factor 1) and CTCF (CCCTC-binding factor zinc finger protein). Figure 1D shows the output interactions resulting from Xist, NXF1, and CTCF. Figure 1C and shows additional levels of interactions among the genes; i.e. many of these are downstream from the first level shown in Figure 1C .
